DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Conway, Kathleen ^a,b   Edmiston, Sharon N ^b   May, Ryan ^c   Kuan, Pei Fen ^d   Chu, Haitao ^e   Bryant, Christopher ^a   Tse, Chiu Kit ^a   Swift Scanlan, Theresa ^b   Geradts, Joseph ^f   Troester, Melissa A ^a,b   Millikan, Robert C ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c EMMES CORPORATION   (United States)

^d Stony Brook University   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; COMPLEMENT COMPONENT C4B; DNA; FIBROBLAST GROWTH FACTOR 2; HISTONE DEACETYLASE 9; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX17; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASCL2 GENE; BCR GENE; BREAST CANCER; C4B GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DAB2IP GENE; DLK1 GENE; DNA METHYLATION; EYA4 GENE; FABP3 GENE; FEMALE; FGF2 GENE; FZD9 GENE; GAS7 GENE; GENE; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE ONTOLOGY; GENETIC VARIABILITY; HDAC9 GENE; HOXA11 GENE; HOXA5 GENE; HOXA9 GENE; HOXB13 GENE; HUMAN; HUMAN TISSUE; IHH GENE; IPF1 GENE; ISL1 GENE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MEST GENE; MME GENE; PAX6 GENE; POMC GENE; POPULATION RESEARCH; PROMOTER REGION; PTGS2 GENE; RARA GENE; RASSF1 GENE; RBP1 GENE; SCGB3A1 GENE; SEPT5 GENE; SERPINA5 GENE; SHORT TERM SURVIVAL; SOX1 GENE; SOX17 GENE; TBX1 GENE; TFF1 GENE; THY1 GENE; TUMOR SUPPRESSOR GENE; BREAST TUMOR; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; EPIDEMIOLOGY; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIGENE FAMILY; MULTIVARIATE ANALYSIS; NORTH CAROLINA; PAGET NIPPLE DISEASE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIGENE FAMILY; MULTIVARIATE ANALYSIS; NORTH CAROLINA; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84988838278     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0450-6     Document Type: Article

References (67)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
4. Polyak K, Shipitsin M, Campbell-Marrotta L, Bloushtain-Qimron N, Park SY: Breast tumor heterogeneity: causes and consequences. Breast Cancer Res 2009, 11:S18.
5. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23.
6. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C: Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 2012, 109:2772-2777.
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
8. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139.
9. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC: Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16:6100-6110.
10. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
11. Plass C: Cancer epigenomics. Hum Mol Genet 2000, 11:2479-2488.
12. Antequera F, Bird A: Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 1993, 90:11995-11999.
13. Bird A, Taggart M, Frommer M, Miller OJ, Macleod D: A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 1985, 40:91-99.
14. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
15. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET: The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 1995, 35:51-60.
16. Moorman PG, Newman B, Millikan RC, Tse CK, Sandler DP: Participation rates in a case-control study: the impact of age, race, and race of interviewer. Ann Epidemiol 1999, 9:188-195.
17. Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC, Newman B: Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence. Breast Cancer Res Treat 1999, 58:31-39.
18. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
19. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
20. Li Y, Millikan RC, Carozza S, Newman B, Liu E, Davis R, Miike R, Wrensch M: p53 mutations in malignant gliomas. Cancer Epidemiol Biomarkers Prev 1998, 7:303-308.
21. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, Kuan PF, Hao H, Carson C, Berwick M, Olilla DW, Thomas NE: DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 2011, 24:352-360.
22. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J, Fan JB: High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006, 16:383-393.
23. Marsit CJ, Christensen BC, Houseman EA, Karagas MR, Wrensch MR, Yeh RF, Nelson HH, Wiemels JL, Zheng S, Posner MR, McClean MD, Wiencke JK, Kelsey KT: Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. Carcinogenesis 2009, 30:416-422.
24. Byun HM, Siegmund KD, Pan F, Weisenberger DJ, Kanel G, Laird PW, Yang AS: Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue-and individual-specific DNA methylation patterns. Hum Mol Genet 2009, 18:4808-4817.
25. Lynch AG, Dunning MJ, Iddawela M, Barbosa-Morais NL, Ritchie ME: Considerations for the processing and analysis of GoldenGate-based two-colour Illumina platforms. Stat Methods Med Res 2009, 18:437-452.
26. The R package. [http://www.r-project.org/]
27. Monti S, Tamayo P, Mesirov J, Golub T: Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data. Mach Learn 2009, 52:91-118.
28. Wilkerson M, Waltman P: ConsensusClusterPlus: ConsensusClusterPlus; R package version 1.16.0; 2013.
29. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 1995, 57:289-300. Series B.
30. Therneau T: A Package for Survival Analysis in S_. R package version 2.37-7; [http://CRAN.R-project.org/package=survival]
31. Therneau T, Grambsch P: Modeling Survival Data: Extending the Cox Model. Statistics for Biology and Health. Springer-Verlag; 2000.
32. Andersen P, Gill R: Cox's regression model for counting processes, a large sample study. Ann Stat 1982, 10:1100-1120.
33. Grambsch P, Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
34. DAVID Bioinformatics Resources 6.7 Functional Annotation Tool. [http://david.abcc.ncifcrf.gov/home.jsp]
35. The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
36. Killian JK, Bilke S, Davis S, Walker RL, Jaeger E, Killian MS, Waterfall JJ, Bibikova M, Fan JB, Smith WI Jr, Meltzer PS: A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology. Am J Pathol 2011, 179:55-65.
37. Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Børresen-Dale AL, Tost J, Kristensen V: Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011, 5:61-76.
38. Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH: Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol 2012, 25:185-196.
39. Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, Ruiz Diaz I, Rezola R, Alberdi MJ, Dopazo J, Montaner D, de Renobales M, Fernández AF, Field JK, Fraga MF, Liloglou T, de Pancorbo MM: DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 2010, 12:R77.
40. Piotrowski A, Benetkiewicz M, Menzel U, Díaz de Ståhl T, Mantripragada K, Grigelionis G, Buckley PG, Jankowski M, Hoffman J, Bala D, Srutek E, Laskowski R, Zegarski W, Dumanski JP: Microarray-based survey of CpG islands identifies concurrent hyper-and hypomethylation patterns in tissues derived from patients with breast cancer. Genes Chromosomes Cancer 2006, 45:656-667.
41. Moelans CB, Verschuur-Maes AH, van Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011, 225:222-231.
42. Virmani A, Rathi A, Sugio K, Sathyanarayana UG, Toyooka S, Kischel FC, Tonk V, Padar A, Takahashi T, Roth JA, Euhus DM, Minna JD, Gazdar AF: Aberrant methylation of TMS1 in small cell, non-small cell lung cancer and breast cancer. Int J Cancer 2003, 106:198-204.
43. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R: Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007, 81:280-287.
44. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M: Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010, 12:R36.
45. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, WolffAC, Cope LM, Sukumar S: Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011, 71:6195-6207.
46. Kamalakaran S, Varadan V, Giercksky Russnes HE, Levy D, Kendall J, Janevski A, Riggs M, Banerjee N, Synnestvedt M, Schlichting E, Kåresen R, Shama Prasada K, Rotti H, Rao R, Rao L, Eric Tang MH, Satyamoorthy K, Lucito R, Wigler M, Dimitrova N, Naume B, Borresen-Dale AL, Hicks JB: DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol 2011, 5:77-92.
47. Christensen BC, Kelsey KT, Zheng S, Houseman EA, Marsit CJ, Wrensch MR, Wiemels JL, Nelson HH, Karagas MR, Kushi LH, Kwan ML, Wiencke JK: Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet 2010, 6:e1001043.
48. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, Sukumar S, Parsons R, Richardson AL, Stampfer MR, Gelman RS, Nikolskaya T, Nikolsky Y, Polyak K: Cell typespecific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A 2008, 105:14076-14081.
49. Tomaskovic-Crook E, Thompson EW, Thiery JP: Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009, 11:213.
50. Cohen AL, Piccolo SR, Cheng L, Soldi R, Han B, Johnson WE, Bild AH: Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Med Genomics 2013, 6:35.
51. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Genome Atlas Research Network: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
52. Shinjo K, Okamoto Y, An B, Yokoyama T, Takeuchi I, Fujii M, Osada H, Usami N, Hasegawa Y, Ito H, Hida T, Fujimoto N, Kishimoto T, Sekido Y, Kondo Y: Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 2012, 33:1277-1285.
53. Zhang QY, Yi DQ, Zhou L, Zhang DH, Zhou TM: Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecol Obstet Invest 2011, 72:183-191.
54. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S: Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008, 3:e3698.
55. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001, 158:1121-1127.
56. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999, 59:5438-5442.
57. Jithesh PV, Risk JM, Schache AG, Dhanda J, Lane B, Liloglou T, Shaw RJ: The epigenetic landscape of oral squamous cell carcinoma. Br J Cancer 2013, 108:370-379.
58. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ: Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 2010, 5:e12616.
59. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA: Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011, 3:75ra25.
60. Roll JD, Rivenbark AG, Jones WD, Coleman WB: DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer 2008, 7:15.
61. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS, Ogino S: DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res 2009, 15:3663-3671.
62. van Hoesel AQ, van de Velde CJ, Kuppen PJ, Putter H, de Kruijf EM, van Nes JG, Giuliano AE, Hoon DS: Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res Treat 2011, 131:859-869.
63. Ulirsch J, Fan C, KnaflG, Wu MJ, Coleman B, Perou CM, Swift-Scanlan T: Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Res Treat 2013, 137:383-396.
64. Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, Issa JP, Hilsenbeck SG, Yu Y: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 2012, 12:243.
65. Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N, European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 2007, 43:1679-1686.
66. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP: Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 2009, 11:R14.
67. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.